BD FACSDiscoverâ"¢ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profilin ...

Shot of Corridor in Working Data Center Full of Rack Servers and Supercomputers with Cloud Storage Advantages Icon Visualization.gettyToday I have a sweet dividend “double shot” for you: The first? A 2.8% payout set to grow thanks to AI—and take the stock price up with it.The second gives you high payouts now, in the form of a monthly-paid 7.8% divvie that also looks set to head higher.Both of these tickers are cheap. In fact, they (and the sector they’re in) could very well be the last bargains on the boar ...

Key Takeaways BDX received IVDR approval for two VIASURE assays, expanding BD MAX respiratory and STI testing in Europe.New BD MAX tests detect COVID-19, flu, RSV, HSV-1/2 and syphilis using a fully automated system.BDX says the expansion improves BD MAX utilization, customer reliance and recurring revenue growth.Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics portfolio in Europe. This follo ...

Market Analysis by covering: Becton Dickinson and Co, iShares U.S. Pharmaceuticals ETF, BlackRock Health Sciences Trust. Read 's Market Analysis on Investing.com ...

FRANKLIN LAKES, N.J., Dec. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays developed by Certest Biotec for use on the BD MAXâ"¢ System. The addition of these new assays to the BD MAXâ"¢ System portfolio enables clinical l ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 全 球 领 先 的 医 疗 技 术 公 司 BD （ Becton, Dick inson and Company ） （ 纽 约 证 券 交 易 所 代 码：BDX）美东时间12月3日宣布，全球正式商业化推出具备突破性光谱和实时细胞成像技术 的新型流式细胞分析仪配置，使不同规模、不同需求和不同预算的学术界、制药和生物技术领 域的更多实验室能够在免疫学、癌症免疫治疗和细胞生物学领域取得新发现。 新 型 BD FACSDi scover™ A8 成 像 光 谱 流 式 分 析 仪 搭 载 了 BD SpectralFX™ 技 术 ， 该 技 术 使 科 学 家 能 够 以 最 佳 分 辨 率 和 灵 敏 度 分 析 单 个 细 胞 多 达 50 种 甚 至 更 多 特 征 ； 还 配 备 了 BD Cel lView™ 成像技术，可实现高速成像，揭示细胞的空间和形态信息（例如单个细胞内蛋白 质的位置），这些信息可实时进行可视化分析。 BD FACSDi scover™ A8成像光谱流式分析仪系 ...

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s MedTech “looks well-positioned on several fronts.” The firm also thinks that ma ...

Wolfe Research upgraded life sciences toolmaker Waters Corporation (WAT) to Outperform from Peer Perform on Wednesday, citing potential tailwinds from its proposed merger with BD's (BDX) Biosciences & Diagnostic Solutions unit. The upgrade comes as Waters (WAT) and Becton, Dickinson ( ...

Key Takeaways BDX partnered with ChemoGLO to improve hazardous drug contamination testing in healthcare settings.The deal supports growth in BDX's MDS unit by combining rapid testing with in-depth contamination analysis.ChemoGLO expects the joint solution to deliver detailed contamination reports within three to five days.Yesterday, Becton, Dickinson and Company (BDX) , popularly known as BD, announced a collaboration with ChemoGLO, a notable name in hazardous drug detection and decontamination. The partner ...